From pioneering World Hepatitis Day to raising alarms on the surge of NAFLD and other liver diseases, abuse of diagnostic ...

From pioneering World Hepatitis Day to raising alarms on the surge of NAFLD and other liver diseases, abuse of diagnostic ...

As the market for weight management and anti-obesity grows rapidly in India, diagnostic players are hoping to cash in on the ...

The maker of Mounjaro and Zepbound becomes only the first pharmaceutical company to enter the elite club, dominated by tech ...

Healthcare giant Eli Lilly is now the first global healthcare company to hit $1 trillion in value riding on the popularity of ...

Eli Lilly hit a $1 trillion valuation, driven by demand for Zepbound and Mounjaro. The first health-care firm ever to join ...

These drugs must be started only after a full medical evaluation, used strictly under medical supervision and avoided ...

These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.

Eli Lilly and Company has announced two significant strategic developments that could reshape its long-term growth trajectory ...

A groundbreaking study has revealed how obesity drug Mounjaro affects brain signals linked to cravings. Researchers observed ...

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.

Explore the rising trend of GLP-1 weight loss drugs, their impact on obesity, costs, and potential generics entering the market.